Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Study of Allogeneic Low Oxygen Mesenchymal Bone Marrow Cells in Subjects With Myocardial Infarction

Conditions:   Myocardial Infarction With/Without ST Segment Elevation;   Allogeneic Low Oxygen Mesenchymal Bone Marrow Cells
Interventions:   Biological: Stem cells;   Other: Placebo
Sponsor:   Altaco XXI, LLP
Recruiting - verified February 2016

Danlou Tablets to Prevent Left Ventricular Remodeling

Conditions:   Left Ventricular Remodeling;   Acute Myocardial Infarction
Interventions:   Drug: Danlou Tablets;   Other: Placebo
Sponsor:   shuai Mao
Completed - verified February 2016

Fractional Flow Reserve Versus Angiography for Guiding Selective Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction

Conditions:   Fractional Flow Reserve;   ST-segment Elevation Myocardial Infarction;   Percutaneous Coronary Intervention
Intervention:  
Sponsor:   Nanjing Medical University
Not yet recruiting - verified January 2016

Accelerated Rule Out of Myocardial Infarction

Condition:   Myocardial Infarction
Intervention:   Procedure: Accelerated, combined biomarker rule-out strategy for MI
Sponsor:   Aarhus University Hospital Skejby
Recruiting - verified February 2016

EXpanded CELL ENdocardiac Transplantation (EXCELLENT)

Condition:   Acute Myocardial Infarction
Interventions:   Drug: PROTHERACYTES;   Device: Standard of Care (Percutaneous Transluminal Coronary Angioplasty and stent(s) implantation)
Sponsor:   CellProthera
Recruiting - verified February 2016

A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction

Conditions:   Myocardial Infarction;   Diabetes Mellitus;   Renal Disease;   Coronary Artery Disease
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel
Sponsors:   University of Patras;   AstraZeneca
Not yet recruiting - verified January 2016

Fractional FLow Reserve And IVUS for Clinical OUtcomes in Patients With InteRmediate Stenosis

Condition:   Stable Angina
Intervention:   Device: Drug-eluting stent
Sponsors:   Seoul National University Hospital;   Ajou University School of Medicine;   Keimyung University Dongsan Medical Center;   Inje University
Not yet recruiting - verified February 2016

Hypothermia as an Adjunctive Therapy to Percutaneous Intervention in Patients With Acute Myocardial Infarction

Conditions:   Hypothermia, Induced;   Rewarming;   Myocardial Infarction;   Percutaneous Cornonary Intervention
Interventions:   Device: Proteus® Cooling System;   Procedure: Primary Percutaneous Coronary Intervention
Sponsors:   University of Sao Paulo General Hospital;   ZOLL Circulation, Inc., USA
Recruiting - verified January 2016

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

Condition:   Thrombosis
Interventions:   Drug: BMS-986141;   Drug: Aspirin;   Other: Placebo
Sponsor:   Bristol-Myers Squibb
Not yet recruiting - verified January 2016

Safety and Exploratory Efficacy Study of UCMSCs in Patients With Ischemic Heart Disease (SEESUPIHD)

Conditions:   Acute Myocardial Infarction;   Myocardial Infarction;   Ischemic Cardiomyopathy
Intervention:   Biological: umbilical cord mesenchymal stem cells
Sponsors:   South China Research Center for Stem Cell and Regenerative Medicine;   Sun Yat-sen University
Not yet recruiting - verified January 2016

Sevoflurane and Percutaneous Coronary Intervention by Stent

Condition:   Myocardial Infarction
Intervention:   Drug: sevoflurane
Sponsor:   Instituto Dante Pazzanese de Cardiologia
Not yet recruiting - verified January 2016

Rivaroxaban ACS Specialist Cohort Event Monitoring Study

Condition:   Acute Coronary Syndrome
Intervention:   Other: This is a non-interventional study
Sponsor:   Drug Safety Research Unit, Southampton, UK
Recruiting - verified February 2016

Short-term Air Pollution Exposure and In-hospital Outcomes in Patients With Acute Myocardial Infraction

Conditions:   Air Pollution;   Acute Myocardial Infarction;   Percutaneous Coronary Intervention
Intervention:  
Sponsors:   Nanjing Medical University;   The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Recruiting - verified January 2016

Restenosis Intrastent: Bioresorbable Vascular Scaffolds Treatment (RIBS VI)

Condition:   Coronary In-stent Restenosis
Intervention:   Device: Bioresorbable vascular scaffold
Sponsors:   Spanish Society of Cardiology;   Hospital Universitario de la Princesa;   Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-IP);   Abbott Vascular;   St. Jude Medical;   Terumo Medical Corporation
Recruiting - verified January 2016

Knowledge Translation for Patients With Acute Coronary Syndromes

Condition:   Acute Coronary Syndromes
Intervention:   Behavioral: knowledge translation
Sponsors:   Montreal General Hospital;   Sanofi;   Canadian Institutes of Health Research (CIHR);   Fonds de la Recherche en Santé du Québec
Completed - verified January 2016

Mobilization of Endothelial Progenitor Cells and Aspirin

Condition:   Hypertrophic Obstructive Cardiomyopathy
Intervention:   Drug: Aspirin
Sponsor:   Ottawa Heart Institute Research Corporation
Not yet recruiting - verified January 2016

Hydroxychloroquine in Acute Coronary Syndrome: Prevention of Recurrent Cardiovascular Events

Conditions:   Myocardial Infarction;   Acute Coronary Syndrome;   Inflammation;   Hydroxychloroquine;   Antirheumatic Agents;   Cardiovascular Diseases;   Angina, Unstable
Interventions:   Drug: Hydroxychloroquine;   Drug: Placebo
Sponsors:   Helsinki University Central Hospital;   Finnish Foundation for Cardiovascular Research;   Orion Corporation, Orion Pharma
Not yet recruiting - verified February 2016

AZD9668, an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

Conditions:   Chronic Graft vs Host Disease;   Chronic Graft-Versus-Host-Disease;   Bronchiolitis Obliterans Syndrome
Intervention:   Drug: AZD9668
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified January 2016

Clinical Performance Evaluation of AQT90 FLEX TnI and TnT

Condition:   Myocardial Infarction
Intervention:  
Sponsor:   Radiometer Medical ApS
Recruiting - verified January 2016

GLP-1 and Hyperoxia for Organ Protection in Heart Surgery

Conditions:   Coronary Disease;   Shock, Cardiogenic;   Renal Failure;   Stroke;   Brain Injury;   Aortic Valve Disease
Interventions:   Drug: Byetta (Lilly, Exenatide);   Drug: Conoxia (AGA, oxygen);   Drug: 20% Human Albumin
Sponsor:   Rigshospitalet, Denmark
Not yet recruiting - verified February 2016

Evaluation of the Roadsaver Stent Used in Conjunction With the Nanoparasol Embolic Protection System for Carotid Artery Stenosis

Condition:   Carotid Artery Stenosis
Interventions:   Device: Roadsaver™ Carotid Artery Stent Device;   Device: Nanoparasol® Embolic Protection System
Sponsor:   Microvention-Terumo, Inc.
Not yet recruiting - verified February 2016

EVOLVE Short DAPT Study

Condition:   Coronary Artery Disease
Interventions:   Drug: 3 months of dual antiplatelet therapy (DAPT);   Device: SYNERGY Stent System
Sponsor:   Boston Scientific Corporation
Recruiting - verified January 2016

Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy

Conditions:   Angina, Stable;   Angina, Unstable;   Anticoagulants
Interventions:   Device: COBRA PzF;   Device: DES
Sponsor:   CeloNova BioSciences, Inc.
Recruiting - verified February 2016

Burden of Illness in Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:   Drug: Standard of care in AF in Denmark
Sponsor:   Bayer
Completed - verified February 2016

Study of High Sensitive Troponin-I Level in End-stage Renal Disease Patients Receiving Hemodialysis

Condition:   End-stage Renal Disease
Intervention:   Other: Hemodialysis
Sponsor:   Chulalongkorn University
Completed - verified January 2016

Optilene® Suture for Coronary Artery Bypass Graft Surgery

Conditions:   Coronary Heart Disease;   Multi Vessel Coronary Artery Disease
Intervention:   Procedure: Coronary Artery Bypass Graft surgery
Sponsors:   Aesculap AG;   B.Braun Surgical SA
Recruiting - verified January 2016

Reverse the HYpoTHyroid Status in Acute Myocardial InfarCtion (RHYTHMIC)

Conditions:   Myocardial Infarction;   Hypothyroidism
Intervention:   Drug: Levothyroxine
Sponsors:   Chinese Academy of Medical Sciences, Fuwai Hospital;   Beijing Municipal Science & Technology Commission;   Peking Union Medical College Hospital;   Peking University Third Hospital;   Beijing Anzhen Hospital;   Beijing Chao Yang Hospital;   Beijing Friendship Hospital;   The Luhe Teaching Hospital of the Capital Medical University
Recruiting - verified August 2015

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Condition:   Peripheral Artery Disease
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban-Placebo
Sponsors:   Bayer;   Janssen Research & Development, LLC;   Colorado Prevention Center
Recruiting - verified February 2016

RIGENERA 2.0 Trial

Conditions:   Anterior Myocardial Infarction;   Heart Failure
Interventions:   Drug: rhu G-CSF;   Drug: optimal standard of care;   Procedure: Myocardial Contrast Echocardiography
Sponsor:   Catholic University of the Sacred Heart
Recruiting - verified January 2016

High-risk Patients in Cardiac Surgery Procedures: HiriSCORE

Condition:   C.Surgical Procedure; Cardiac
Intervention:  
Sponsors:   University of Sao Paulo General Hospital;   InCor Heart Institute;   Cardiology Institute of the Distrito Federal, Brazil;   Clinical Hospital Samuel Libânio of Pouso Alegre, Brazil;   Beneficência Portuguesa of São Paulo, Brazil;   Hospital Clínico Universitario de Valladolid;   National Institute of Cardiology, Laranjeiras, Brazil;   Russian Cardiology Research and Production Center, Russian;   La Princesa University Hospital Madrid, Spain;   TotalCor Hospital, Brazil;   Royal Adelaide Hospital;   Santa Casa de Misericórdia of Marília, Brazil;   Hospital de Base
Active, not recruiting - verified June 2015

IMproving reModeling in Acute myoCardial Infarction Using Live and Asynchronous TElemedicine.

Conditions:   Left Ventricular Remodeling;   Medication Adherence;   Acute Coronary Syndrome
Intervention:   Other: Telemedicine
Sponsors:   National University Heart Centre, Singapore;   National University, Singapore;   National University Hospital, Singapore;   Tan Tock Seng Hospital
Recruiting - verified January 2016

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Recruiting - verified January 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsor:   Bayer
Recruiting - verified February 2016

A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction

Condition:   Heart Failure
Interventions:   Drug: BAY1142524;   Drug: BAY1142524;   Drug: BAY1142524;   Drug: BAY1142524;   Drug: Placebo
Sponsor:   Bayer
Active, not recruiting - verified February 2016

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Condition:   Cost Sharing, Acute Coronary Syndrome,
Intervention:   Other: Study voucher card
Sponsors:   AstraZeneca;   Duke Clinical Research Institute
Recruiting - verified January 2016

COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial

Condition:   ST Elevation Acute Myocardial Infarction
Interventions:   Drug: Exenatide;   Other: Remote Ischemic Conditioning (RIC);   Drug: Placebo
Sponsor:   Hospital Universitari Vall d'Hebron Research Institute
Not yet recruiting - verified January 2016

Brilinta Taiwan Post Approval Safety Study

Condition:   Non ST-elevation Myocardial Infarction
Intervention:   Drug: Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
Sponsor:   AstraZeneca
Recruiting - verified February 2016

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

Conditions:   Coronary Artery Disease;   Atherosclerosis, Coronary;   Myocardial Ischemia;   Ischemic Heart Disease;   Acute Coronary Syndrome;   Angina Pectoris
Interventions:   Device: Orsiro DES;   Device: Xience DES
Sponsors:   Biotronik, Inc.;   Biotronik AG;   Harvard Clinical Research Institute;   Medstar Research Institute
Recruiting - verified February 2016

Prevention of Myocardial Injury in Non-cardiac Surgery

Conditions:   Myocardial Injury;   Myocardial Infarction
Intervention:   Procedure: Remote ischemic preconditioning
Sponsor:   University Hospital Koge
Recruiting - verified February 2016

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Conditions:   HIV Infections;   Cardiovascular Diseases
Interventions:   Drug: Pitavastatin;   Drug: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Heart, Lung, and Blood Institute (NHLBI);   Kowa Pharmaceuticals America, Inc.
Recruiting - verified February 2016

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Acute Leukemia;   Multiple Myeloma
Interventions:   Biological: Rituximab;   Drug: Conditioning Chemotherapy;   Drug: TMS;   Drug: FLAG;   Drug: EPOCH-F;   Procedure: Hematopoietic Stem Cell Transplant;   Drug: Palifermin
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified December 2015

Long-term Exercise in Older Cardiac Patients

Condition:   Coronary Artery Disease
Interventions:   Behavioral: SystemCHANGE;   Behavioral: CHANGE+;   Behavioral: Usual Care
Sponsor:   Case Western Reserve University
Completed - verified January 2016

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

Condition:   Stroke
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin (Acetylsalicylic acid, BAY1019036);   Other: Rivaroxaban-Placebo;   Other: Aspirin-Placebo
Sponsors:   Bayer;   Janssen, LP;   Hamilton Health Sciences Cooperation, Population Health Research Institute
Recruiting - verified February 2016

Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction by Biomarkers

Conditions:   Acute Myocardial Infarction (AMI);   Acute Coronary Syndrome (ACS);   ST Elevation (STEMI) Myocardial Infarction;   Ischemic Reperfusion Injury;   Non-ST Elevation (NSTEMI) Myocardial Infarction;   Angina, Unstable
Intervention:   Drug: Oxygen
Sponsors:   Karolinska Institutet;   University Hospital, Linkoeping
Active, not recruiting - verified January 2016

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Acetylsalicylic acid;   Drug: Rivaroxaban;   Drug: Clopidogrel;   Drug: Ticagrelor
Sponsors:   Janssen Research & Development, LLC;   Bayer;   Duke Clinical Research Institute;   Harvard Medical School
Recruiting - verified January 2016

Effects of Oxygen Treatment on Mechanisms Involved in Ischemia-reperfusion Injury: A Pilot Study in Healthy Volunteers

Conditions:   Myocardial Infarction;   Inflammation;   Acute Coronary Syndrome (ACS);   Reperfusion Injury
Interventions:   Biological: Salmonella typhi vaccine (Typhim Vi®);   Drug: Oxygen (Oxymask®);   Drug: Atorvastatin
Sponsors:   Karolinska Institutet;   University Hospital, Linkoeping
Active, not recruiting - verified January 2016

A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction

Conditions:   Heart Attack;   NSTEMI
Interventions:   Biological: AMI MultiStem cells;   Other: Sham
Sponsors:   Athersys, Inc;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2016

Study of Ticagrelor Versus Aspirin Treatment in Patients With Myocardial Injury Post Major Non-cardiac Surgery

Condition:   Myocardial Injury
Interventions:   Drug: ticagrelor;   Drug: aspirin
Sponsors:   The Cleveland Clinic;   AstraZeneca
Recruiting - verified January 2016

Early Feasibility Study of the Neovasc Tiara™ Mitral Valve System

Condition:   Mitral Valve Regurgitation
Intervention:   Device: Mitral valve replacement
Sponsor:   Neovasc Inc.
Recruiting - verified January 2016

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Conditions:   Stroke;   Secondary Prevention
Interventions:   Drug: optional ASA as comedication;   Drug: placebo to ASA;   Drug: placebo to optional ASA as comedication;   Drug: placebo to dabigatran etexilate;   Drug: ASA 100 mg;   Drug: dabigatran etexilate
Sponsor:   Boehringer Ingelheim
Recruiting - verified January 2016

Exercise as a Life-long Medicine in Patients With Coronary Artery Disease

Conditions:   Cardiovascular Diseases;   Myocardial Infarction;   Angina (Stable)
Interventions:   Behavioral: high-intensity exercise training;   Behavioral: web-based follow-up program;   Behavioral: usual care
Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital;   Levanger Hospital
Recruiting - verified February 2016

Circadian Rhythms and Cardiovascular Risk

Condition:   Obstructive Sleep Apnea
Intervention:   Behavioral: Forced Desynchrony
Sponsor:   Oregon Health and Science University
Recruiting - verified January 2016

Arrhythmia Prediction Trial

Conditions:   Myocardial Infarction;   Dilated Cardiomyopathy;   Heart Failure
Intervention:  
Sponsor:   University of Athens
Recruiting - verified January 2016

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Epoetin alfa
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified February 2016

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis.

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Placebo
Sponsors:   AstraZeneca;   FibroGen
Active, not recruiting - verified February 2016

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: Dabigatran Etexilate 110mg;   Drug: Warfarin 3mg;   Drug: Aspirin;   Drug: Dabigatran Etexilate 150mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 5mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 1mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified January 2016

Multidetector Coronary CT In Vasospastic Angina

Condition:   Vasospastic Angina
Interventions:   Procedure: Positive CAG with EG test;   Procedure: Negative CAG with EG test
Sponsor:   Dong-A University
Recruiting - verified February 2016

TEAMS (Troponin Elevation After Major Surgery) Study

Conditions:   Perioperative Myocardial Infarction;   Disability
Intervention:  
Sponsor:   University Health Network, Toronto
Active, not recruiting - verified November 2015

A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Losmapimod 7.5 mg twice daily;   Drug: Placebo twice daily
Sponsors:   GlaxoSmithKline;   The TIMI Study Group
Recruiting - verified January 2016

Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction

Conditions:   Myocardial Infarction;   Percutaneous Coronary Intervention;   Thrombolytic Therapy
Interventions:   Drug: Prourokinase;   Drug: Tirofiban;   Drug: normal saline
Sponsor:   Fudan University
Recruiting - verified February 2016

The Short- and Long Term Outcomes of Early Routine PCI With the Standard Treatment in Low-intermediate Risk ST-elevation Myocardial Infarction Patients Who Successfully Fibrinolysis.

Condition:   ST-elevation Myocardial Infarction
Intervention:   Other: Percutaneous coronary intervention
Sponsor:   Chiang Mai University
Completed - verified May 2014

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

Condition:   Acute Myocardial Infarction
Interventions:   Biological: CSL112;   Biological: Placebo
Sponsor:   CSL Behring
Active, not recruiting - verified February 2016

Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary Events

Condition:   Pulmonary Disease, Chronic Obstructive
Intervention:  
Sponsor:   Boehringer Ingelheim
Completed - verified January 2016

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

Conditions:   Heart Failure;   Respiratory Insufficiency;   Stroke Acute;   Infectious Diseases;   Rheumatic Diseases
Interventions:   Drug: Rivaroxaban, 10 mg;   Drug: Rivaroxaban, 7.5 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified January 2016

Prognostic Impact of Sleep Apnea on Cardiovascular Morbidity and Mortality, in End Stage Renal Disease Patients

Conditions:   Obstructive Sleep Apnea;   End Stage Renal Disease
Interventions:   Other: No Sleep Apnea;   Other: Sleep Apnea - untreated;   Device: Sleep Apnea - treated
Sponsor:   Centre Hospitalier Universitaire Vaudois
Recruiting - verified January 2016

Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol

Conditions:   Aortic Valve Disease;   Coronary Artery Disease (CAD)
Interventions:   Drug: Custodiol-N;   Drug: Custodiol
Sponsor:   Dr. F. Köhler Chemie GmbH
Recruiting - verified January 2016

Ventricular Remodeling and Heart Failure After Myocardial Infarction: A Community Study

Conditions:   Heart Failure;   Myocardial Infarction
Intervention:  
Sponsor:   Mayo Clinic
Recruiting - verified February 2016

Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury

Condition:   Acute Myocardial Infarction
Interventions:   Drug: liraglutide (Novo Nordisk, Bagsværd, Denmark);   Drug: liraglutide placebo (Novo Nordisk)
Sponsor:   Chen Wei Ren, MD
Recruiting - verified February 2016

The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation

Conditions:   Antibody-mediated Rejection;   Hyperacute Rejection of Cardiac Transplant;   Left Ventricular Dysfunction;   Cardiac Allograft Vasculopathy;   Heart Graft Dysfunction
Intervention:   Drug: Eculizumab
Sponsors:   Cedars-Sinai Medical Center;   Alexion Pharmaceuticals
Enrolling by invitation - verified February 2016

Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

Conditions:   Breast Cancer;   Breast Tumors;   Cancer of Breast
Interventions:   Drug: Metformin;   Drug: Atorvastatin;   Procedure: Breast surgery
Sponsor:   Columbia University
Recruiting - verified February 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified January 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified January 2016

Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

Conditions:   Atrial Fibrillation;   Stroke
Interventions:   Drug: Apixaban;   Drug: aspirin
Sponsors:   Population Health Research Institute;   Bristol-Myers Squibb;   Pfizer;   Medtronic
Recruiting - verified February 2016

Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)

Condition:   HIV-1 Infection
Intervention:   Drug: Telmisartan
Sponsors:   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting - verified January 2016

A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)

Conditions:   Coronary Artery Disease;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Stenosis
Interventions:   Device: XIENCE V EECSS;   Device: ABSORB BVS System
Sponsor:   Abbott Vascular
Active, not recruiting - verified January 2016

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified January 2016

A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)

Condition:   Diabetes Mellitus, Type 2, Kidney Disease, Chronic
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Withdrawn - verified February 2016

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure

Conditions:   Heart Failure;   Coronary Artery Disease
Interventions:   Drug: Rivaroxaban;   Drug: Placebo;   Other: Standard of care for heart failure and coronary artery disease
Sponsors:   Janssen Research & Development, LLC;   Bayer
Recruiting - verified January 2016

China Acute Myocardial Infarction Registry

Condition:   Acute Myocardial Infarction
Intervention:  
Sponsor:   Chinese Academy of Medical Sciences, Fuwai Hospital
Recruiting - verified January 2016

The Role of Biomarkers and Echocardiography in Prediction of Prognosis of Chronic Heart Failure Patients

Condition:   Heart Failure
Intervention:   Other: Observational study; no intervention.
Sponsors:   Erasmus Medical Center;   Medical Center Alkmaar
Recruiting - verified January 2016

An Efficacy and Outcome Study of Supplemental Oxygen Treatment in Patients With Suspected Myocardial Infarction

Conditions:   Acute Coronary Syndrome;   Non-ST Elevation (NSTEMI) Myocardial Infarction;   Acute ST Segment Elevation Myocardial Infarction;   Angina, Unstable
Intervention:   Drug: Oxygen
Sponsors:   Karolinska Institutet;   Swedish Heart Lung Foundation;   Swedish Foundation for Strategic Research;   The Swedish Research Council
Active, not recruiting - verified January 2016

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Condition:   Prevention & Control
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin;   Drug: Aspirin placebo;   Drug: Rivaroxaban placebo;   Drug: Pantoprazole
Sponsors:   Bayer;   Hamilton Health Sciences Corporation, Population Health Research Institute
Recruiting - verified February 2016

On-treatment PLAtelet Reactivity-guided Therapy Modification FOR ST-segment Elevation Myocardial Infarction

Condition:   Acute ST-elevation Myocardial Infarction
Intervention:   Drug: Antiplatelet Regimen Modification (aspirin or ticagrelor)
Sponsor:   Clinical Centre of Serbia
Recruiting - verified January 2016

Optical Frequency Domain Imaging (OFDI) and Vascular Healing After Stent Placement Diabetics Presenting With Acute Coronary Syndrome

Condition:   Coronary Artery Disease
Intervention:   Device: Resolute Integrity stent
Sponsor:   Emory University
Active, not recruiting - verified February 2016

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed - verified January 2016

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Condition:   Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Omarigliptin;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified January 2016

A Study of Evacetrapib in High-Risk Vascular Disease

Condition:   Cardiovascular Diseases
Interventions:   Drug: Evacetrapib;   Drug: Placebo
Sponsors:   Eli Lilly and Company;   The Cleveland Clinic
Active, not recruiting - verified January 2016

ClearWay Rx Readmission Registry

Condition:   Acute Myocardial Infarction
Intervention:   Device: ClearWay™ Rx catheter
Sponsor:   Cardiovascular Institute of the South Clinical Research Corporation
Completed - verified January 2016

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified January 2016

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab;   Drug: placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified February 2016

A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta

Condition:   Acute Coronary Syndromes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified January 2016

Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

Condition:   Hodgkin Lymphoma, Adult
Interventions:   Drug: Brentuximab vedotin;   Drug: ABVD
Sponsors:   UNC Lineberger Comprehensive Cancer Center;   Seattle Genetics, Inc.
Suspended - verified February 2016

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Coronary Artery Disease;   Heart Diseases;   Myocardial Ischemia
Interventions:   Procedure: cardiac catheterization;   Procedure: coronary artery bypass graft surgery;   Procedure: percutaneous coronary intervention;   Behavioral: Lifestyle;   Drug: Medication
Sponsors:   New York University School of Medicine;   New York University;   Stanford University;   National Heart, Lung, and Blood Institute (NHLBI);   Albany Stratton VA Medical Center;   Cedars-Sinai Medical Center;   Columbia University;   Duke University;   East Carolina University;   Emory University;   Harvard University;   Massachusetts General Hospital;   Montreal Heart Institute;   University of British Columbia;   University of Missouri, Kansas City;   Vanderbilt University
Recruiting - verified January 2016

Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation

Condition:   HIV-1 Infection
Interventions:   Drug: Pravastatin sodium;   Drug: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate;   Drug: Pravastatin sodium
Sponsors:   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Withdrawn - verified January 2016

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified January 2016

Predictors of Post Operative Outcome in Peripheral Vascular Surgical Patients

Condition:   Vascular Diseases
Intervention:  
Sponsor:   York Teaching Hospitals NHS Foundation Trust
Completed - verified February 2015

Study of the Natural History of FFR Guided Percutaneous Coronary Intervention

Condition:   Coronary Artery Disease
Intervention:  
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea;   St. Jude Medical (Hong Kong) Limited
Recruiting - verified January 2016

Comparison Between High-sensitivity Cardiac Troponin T and Standard Tnl Assays in Early Cardiac Ischemia Detection

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   University of Lausanne Hospitals
Completed - verified January 2016

A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention

Condition:   Myocardial Infarction
Interventions:   Procedure: Percutaneous Coronary Intervention (PCI);   Drug: RO4905417;   Drug: RO4905417;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Remote Ischemic Preconditioning in High Risk Cardiovascular Surgery Patients

Conditions:   Death;   Stroke;   Low Cardiac Output Syndrome;   Myocardial Infarction;   Renal Failure;   Pulmonary Failure
Interventions:   Other: Remote ischemic preconditioning stimulus;   Other: control
Sponsor:   Queen's University
Completed - verified February 2016

Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans

Conditions:   Bronchiolitis Obliterans;   Graft vs Host Disease
Intervention:   Drug: Cyclosporine Inhalation Solution
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified October 2015

Morphine In Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Drug: morphine chlorhydrate;   Drug: saline solution
Sponsors:   French Cardiology Society;   Institut National de la Santé Et de la Recherche Médicale, France
Active, not recruiting - verified February 2016

Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty

Condition:   Saphenous Vein Graft Atherosclerosis
Interventions:   Device: Bare Metal Stent;   Device: Drug-Eluting Stent;   Drug: Blinded clopidogrel;   Drug: Placebo;   Drug: Thienopyridine (open-label)
Sponsor:   VA Office of Research and Development
Active, not recruiting - verified February 2016

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Molecular and Morphologic Characterization of Circulating Endothelial Cells

Condition:   Acute Myocardial Infarction
Intervention:  
Sponsor:   Scripps Translational Science Institute
Recruiting - verified January 2016

Strengthening Transplantation Effects of Bone Marrow Mononuclear Cells With Atorvastatin in Myocardial Infarction

Conditions:   Myocardial Infarction;   Stem Cell Transplantation;   Angioplasty, Transluminal, Percutaneous Coronary
Intervention:   Drug: Atorvastatin and mononuclear cells transplantation
Sponsor:   Chinese Academy of Medical Sciences, Fuwai Hospital
Enrolling by invitation - verified January 2016

Autologous Cell Therapy After Stroke

Condition:   Stroke
Interventions:   Biological: autologous bone marrow mononuclear cell transfusion;   Biological: marrow stromal cells;   Drug: placebo
Sponsors:   University of California, Irvine;   University of California, San Diego
Withdrawn - verified February 2016

Ventricular Tachycardia (VT) Ablation Versus Enhanced Drug Therapy

Condition:   Recurrent Ventricular Tachycardia
Interventions:   Procedure: Catheter Ablation;   Drug: Aggressive Antiarrhythmic Therapy (Amiodarone)
Sponsors:   John Sapp;   St. Jude Medical;   Biosense Webster, Inc.;   Canadian Institutes of Health Research (CIHR)
Completed - verified January 2016

Safety and Efficacy of SeeMore (TM) in Heart Patients

Condition:   Myocardial Infarction
Intervention:   Drug: SeeMore(TM)
Sponsor:   Eagle Vision Pharmaceutical Corp.
Completed - verified February 2016

A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.

Condition:   Anemia
Interventions:   Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta);   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
Sponsor:   Hoffmann-La Roche
Active, not recruiting - verified February 2016

Study of Ambrisentan in Subjects With Pulmonary Hypertension

Condition:   Pulmonary Hypertension
Intervention:   Drug: Ambrisentan
Sponsor:   Gilead Sciences
Active, not recruiting - verified January 2016

Ischemia Driven Enoxaparin Therapy in ACS Presenting as Low Risk (IDEAL)

Condition:   Unstable Angina
Intervention:   Drug: enoxaparin
Sponsors:   Canadian Heart Research Centre;   Sanofi
Terminated - verified January 2016

Stem Cell Transplant With Th2/Tc2 Cells to Treat Advanced Breast Cancer

Condition:   Breast Neoplasms
Intervention:   Drug: Th2/Tc2 Cells
Sponsor:   National Cancer Institute (NCI)
Completed - verified August 2013

Minnesota Heart Survey - Mortality and Morbidity

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases;   Myocardial Infarction;   Death, Sudden, Cardiac
Intervention:  
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2016

Intermittent ST Depression and Prognosis After Myocardial Infarction

Conditions:   Cardiovascular Diseases;   Myocardial Infarction;   Heart Diseases
Intervention:  
Sponsors:   New York University School of Medicine;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified January 2016

Minnesota Heart Survey - Risk Factor Survey

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Cerebrovascular Accident;   Coronary Disease;   Hypertension;   Myocardial Infarction
Intervention:  
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2016

Novel Hemostatic Cardiac Risk Factors in Framingham

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Death, Sudden, Cardiac;   Myocardial Infarction;   Thrombosis;   Atherosclerosis;   Carotid Artery Diseases
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified March 2005